市場調査レポート
商品コード
1357250

代謝アッセイの世界市場:製品別、技術別、用途別、エンドユーザー別、地域別-2028年までの予測

Metabolism Assays Market by Product, Technology, Application (Diagnostics, Research), End User, & Region - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 188 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
代謝アッセイの世界市場:製品別、技術別、用途別、エンドユーザー別、地域別-2028年までの予測
出版日: 2023年09月28日
発行: MarketsandMarkets
ページ情報: 英文 188 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

代謝アッセイの市場規模は、予測期間中にCAGR 7.8%で拡大し、2023年の14億米ドルから2028年には21億米ドルに達すると予測されています。

同市場の成長は、政府による代謝研究の推進と資金提供、フィットネスやスポーツ産業における代謝アッセイ法の利用の拡大、早期診断に対する意識の高まりが主な要因となっています。しかし、メタボリズムアッセイの高コストに関する問題が、この市場の成長を抑制しています。

製品別では、2022年には、アッセイキット&試薬セグメントが製品市場を独占しました。また、このセグメントは予測期間中に最も高いCAGRで成長すると予測されています。大きなシェアは、ウェアラブルデバイスなどの技術との統合や、主要用途である診断での幅広い使用によるものです。

エンドユーザー別では、2022年には、製薬&バイオテクノロジー企業およびCRO&学術研究機関セグメントが代謝アッセイ市場を独占しました。診断ラボセグメントは予測期間中に最も高いCAGRで成長すると予測されています。このセグメントの大きなシェアは、代謝研究に対する製薬&バイオテクノロジー企業による研究開発投資の増加によるものと考えられます。

地域別では予測期間中、北米において高い市場シェアが見込まれます。創薬、毒性試験、開発に携わる製薬・バイオテクノロジー産業の堅調な存在と、対象疾患人口の増加が代謝アッセイ市場の成長を支えています。しかし、アジア太平洋は予測期間中に最も高いCAGRを達成すると予想されています。

当レポートでは、世界の代謝アッセイ市場について調査し、製品別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • 規制分析
  • 貿易分析
  • 技術分析
  • 2023年~2024年の主な会議とイベント
  • ビジネスに影響を与える動向/混乱
  • 主要な利害関係者と購入基準

第6章 代謝アッセイ市場、製品別

  • イントロダクション
  • アッセイキットと試薬
  • 計測器とアナライザー

第7章 代謝アッセイ市場、技術別

  • イントロダクション
  • 比色分析
  • 蛍光分析
  • 分光分析

第8章 代謝アッセイ市場、用途別

  • イントロダクション
  • 診断
  • 研究

第9章 代謝アッセイ市場、エンドユーザー別

  • イントロダクション
  • 病院
  • 診断研究所
  • 製薬・バイオテクノロジー企業、CRO・学術研究機関

第10章 代謝アッセイ市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第11章 競合情勢

  • 概要
  • 主要参入企業戦略/有力企業
  • 市場主要参入企業の収益シェア分析
  • 市場ランキング分析
  • 企業評価クワドラント(2022年)
  • スタートアップ/中小企業向けの企業評価クアドラント(2022年)
  • 競合ベンチマーキング
  • 競合シナリオ

第12章 企業プロファイル

  • 主要参入企業
    • THERMO FISHER SCIENTIFIC INC.
    • MERCK KGAA
    • ABCAM PLC.
    • AGILENT TECHNOLOGIES INC.
    • KANEKA EUROGENTEC S.A.
    • SARTORIUS AG
    • PROMEGA CORPORATION
    • ELABSCIENCE BIOTECHNOLOGY INC.
    • RAYBIOTECH LIFE, INC.
    • BMG LABTECH
    • BIOTREND CHEMIKALIEN GMBH
  • その他の企業
    • 3H BIOMEDICAL AB
    • BIOASSAY SYSTEMS
    • EMELCA BIOSCIENCE
    • CREATIVE BIOARRAY
    • TEMPO BIOSCIENCE, INC.
    • NCARDIA
    • NOVOCIB
    • ETON BIOSCIENCE, INC.
    • CAYMAN CHEMICAL COMPANY
    • ENZO LIFE SCIENCES, INC.
    • ABNOVA CORPORATION

第13章 付録

目次
Product Code: MD 8811

The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth of this market is majorly driven by the promotion of metabolic research and funding by the government, the growing use of metabolism assays in fitness and sports industry, and an increase in the awareness of early diagnosis. However, issues related high cost of metabolism assays restrain the growth of this market.

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredUSD
SegmentsProduct,Technology,Application,End User,Region
Regions coveredNorth America, Europe, APAC, RoW

"The assay kits & reagents segment accounted for the highest market share in the metabolism assays market, by product, during the forecast period."

Based on the product segment, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share is due to their integration with technologies, such as wearable devices and wide use in diagnostics as it is the major application.

"Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes accounted for the highest CAGR during the forecast period."

Based on end users, the metabolism assays market is segmented into hospitals, diagnostic laboratories, and pharmaceutical & biotechnology companies and CROs & academic research institutes. The pharmaceutical & biotechnology companies and CROs & academic research institutes segment dominated the metabolism assays market in 2022. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to increasing R&D investments by pharmaceutical & biotechnology companies on metabolic research.

"The North America segment accounted for the highest market share in the metabolism assays market, by region, during the forecast period."

Based on the region, the global metabolism assays market is categorized into North America, Europe, Asia Pacific, and Rest of the World. During the forecast period North America is expected to witness a high market share. The presence of robust pharma & biotech industries who are involved in drug discover, toxicity testing & development and the increasing target disease population are supporting the growth of the metabolism assays market. However, Asia Pacific is expected to register highest CAGR during the forecast period.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Company Type: Tier 1 (30%), Tier 2 (48%), and Tier 3 (22%)
  • By Designation: C-level (28%), Director-level (33%), and Others (39%)
  • By Region: North America (21%), Asia-Pacific (34%), Europe (30%), and RoW (15%)

Prominent companies include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan).

Research Coverage

This research report categorizes the metabolism assays market by product, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the metabolism assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the metabolism assays market. Competitive analysis of upcoming startups in the metabolism assays market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall metabolism assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the metabolism assays market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the metabolism assays market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the metabolism assays market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the metabolism assays market
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US), among others in the metabolism assays market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
    • TABLE 2 KEY DATA FROM PRIMARY SOURCES
    • FIGURE 2 KEY INDUSTRY INSIGHTS
      • 2.1.2.1 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH
    • 2.2.1 GROWTH FORECAST
    • 2.2.2 CAGR PROJECTIONS
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.3 TOP-DOWN APPROACH
    • FIGURE 7 METABOLISM ASSAYS MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE/RANKING ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 IMPACT OF RECESSION

3 EXECUTIVE SUMMARY

    • FIGURE 9 METABOLISM ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    • FIGURE 10 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    • FIGURE 11 METABOLISM ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 METABOLISM ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 REGIONAL SNAPSHOT OF METABOLISM ASSAYS MARKET

4 PREMIUM INSIGHTS

  • 4.1 METABOLISM ASSAYS MARKET OVERVIEW
    • FIGURE 14 INCREASED PREVALENCE OF OBESITY AND DIABETES TO DRIVE METABOLISM ASSAYS MARKET
  • 4.2 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT (2022)
    • FIGURE 15 ASSAY KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE IN 2022
  • 4.3 REGIONAL GROWTH OPPORTUNITIES IN METABOLISM ASSAYS MARKET
    • FIGURE 16 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 METABOLISM ASSAYS MARKET: REGIONAL MIX
    • FIGURE 17 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
  • 4.5 METABOLISM ASSAYS MARKET: DEVELOPED VS. EMERGING ECONOMIES
    • FIGURE 18 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN METABOLISM ASSAYS MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing funding and investments in metabolic research
      • 5.2.1.2 Drug discovery and development
      • 5.2.1.3 Rise in prevalence of chronic diseases
      • 5.2.1.4 Increased use of metabolism assays in fitness and sports
      • 5.2.1.5 Growing demand for personalized medicines
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of metabolism assay analyzers
      • 5.2.2.2 Presence of alternative methods and techniques
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Integration with wearable devices
      • 5.2.3.2 Growing life science research in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexity of assay development
  • 5.3 PRICING ANALYSIS
    • TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS
  • 5.4 PATENT ANALYSIS
    • FIGURE 20 PATENT ANALYSIS FOR METABOLISM ASSAYS (JANUARY 2013-DECEMBER 2022)
    • 5.4.1 LIST OF KEY PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 22 METABOLISM ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 23 METABOLISM ASSAYS MARKET: ECOSYSTEM ANALYSIS
    • 5.7.1 METABOLISM ASSAYS MARKET: ROLE IN ECOSYSTEM
    • FIGURE 24 KEY PLAYERS IN METABOLISM ASSAYS MARKET
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 PORTER'S FIVE FORCES ANALYSIS: METABOLISM ASSAYS MARKET
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
    • TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
      • 5.9.1.2 Canada
    • TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.9.2 EUROPE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 Japan
    • TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
      • 5.9.3.2 China
    • TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES
      • 5.9.3.3 India
  • 5.10 TRADE ANALYSIS
    • TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 11 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023-2024
  • 5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES
    • 5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
    • TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
    • 5.14.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
    • TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS

6 METABOLISM ASSAYS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 14 METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 ASSAY KITS & REAGENTS
    • 6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY
    • TABLE 15 ASSAY KITS AVAILABLE IN MARKET
    • TABLE 16 METABOLISM ASSAYS MARKET: ASSAY KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS & ANALYZERS
    • 6.3.1 AUTOMATION IN INSTRUMENTS, ALONG WITH ADOPTION OF SOFTWARE, TO DRIVE SEGMENTAL GROWTH
    • TABLE 17 INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
    • TABLE 18 METABOLISM ASSAYS MARKET: INSTRUMENTS & ANALYZERS, BY REGION, 2021-2028 (USD MILLION)

7 METABOLISM ASSAYS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 19 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 COLORIMETRY
    • 7.2.1 COST-EFFECTIVENESS TO DRIVE MARKET
    • TABLE 20 METABOLISM ASSAYS MARKET FOR COLORIMETRY, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 FLUORIMETRY
    • 7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO DRIVE MARKET
    • TABLE 21 METABOLISM ASSAYS MARKET FOR FLUORIMETRY, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 SPECTROMETRY
    • 7.4.1 INCREASED IMPORTANCE IN RESEARCH AND CLINICAL DIAGNOSTICS TO DRIVE MARKET
    • TABLE 22 METABOLISM ASSAYS MARKET FOR SPECTROMETRY, BY REGION, 2021-2028 (USD MILLION)

8 METABOLISM ASSAYS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 23 METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 8.2 DIAGNOSTICS
    • 8.2.1 GROWING PREVALENCE OF METABOLIC AND CHRONIC DISEASES TO DRIVE MARKET
    • TABLE 24 DIAGNOSTICS: METABOLISM ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 25 METABOLISM ASSAYS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.2 DIABETES
    • TABLE 26 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR DIABETES, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.3 OBESITY
    • TABLE 27 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OBESITY, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.4 CANCER
    • TABLE 28 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.5 CARDIOVASCULAR DISEASES
    • TABLE 29 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.6 OTHER DIAGNOSTICS
    • TABLE 30 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OTHER DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 RESEARCH
    • 8.3.1 INCREASE IN AWARENESS OF METABOLISM ASSAY IN DISEASE RESEARCH
    • TABLE 31 RESEARCH: METABOLISM ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)

9 METABOLISM ASSAYS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 32 METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 HOSPITALS
    • 9.2.1 AFFORDABILITY AND CONVENIENCE TO DRIVE SEGMENT
    • TABLE 33 METABOLISM ASSAYS MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 DIAGNOSTIC LABORATORIES
    • 9.3.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
    • TABLE 34 METABOLISM ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES
    • 9.4.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
    • TABLE 35 METABOLISM ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)

10 METABOLISM ASSAYS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 36 METABOLISM ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: METABOLISM ASSAYS MARKET SNAPSHOT
    • TABLE 37 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 High rate of drug discovery and toxicity testing to drive market
    • TABLE 42 US: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 43 US: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 44 US: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 45 US: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 High prevalence of obesity to fuel market growth
    • TABLE 46 CANADA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 47 CANADA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 48 CANADA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 49 CANADA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 50 EUROPE: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 53 EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Growth of pharmaceutical companies to drive market
    • TABLE 55 GERMANY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 56 GERMANY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 57 GERMANY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 58 GERMANY: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Growing cancer research funding to drive market
    • TABLE 59 UK: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 60 UK: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 61 UK: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 62 UK: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising obese population and prevalence of metabolic disorders to drive market
    • TABLE 63 FRANCE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 64 FRANCE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 65 FRANCE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 66 FRANCE: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Increasing prevalence of aging population and diabetes to drive market
    • TABLE 67 SPAIN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 68 SPAIN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 69 SPAIN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 70 SPAIN: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 ITALY
      • 10.3.6.1 Growth of pharmaceutical industry to boost market
    • TABLE 71 ITALY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 72 ITALY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 73 ITALY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 74 ITALY: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 75 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 76 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 77 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 78 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: METABOLISM ASSAYS MARKET SNAPSHOT
    • 10.4.1 RECESSION IMPACT
    • TABLE 79 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Government initiatives to drive market
    • TABLE 84 JAPAN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 85 JAPAN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 86 JAPAN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 87 JAPAN: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing health awareness to drive demand
    • TABLE 88 CHINA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 89 CHINA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 90 CHINA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 91 CHINA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Prevalence of chronic diseases to fuel demand
    • TABLE 92 INDIA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 93 INDIA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 94 INDIA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 95 INDIA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 96 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 97 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 98 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 99 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • 10.5.1 RECESSION IMPACT
    • TABLE 100 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 101 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 102 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 103 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN METABOLISM ASSAYS MARKET
  • 11.4 MARKET RANKING ANALYSIS
    • FIGURE 30 METABOLISM ASSAYS MARKET RANKING ANALYSIS, BY KEY PLAYER (2022)
  • 11.5 COMPANY EVALUATION QUADRANT (2022)
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 31 METABOLISM ASSAYS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
  • 11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 32 METABOLISM ASSAY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
  • 11.7 COMPETITIVE BENCHMARKING
    • TABLE 105 METABOLISM ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 106 PRODUCT FOOTPRINT OF KEY PLAYERS
    • TABLE 107 REGIONAL FOOTPRINT OF KEY PLAYERS
    • TABLE 108 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES
    • TABLE 109 PRODUCT LAUNCHES, JANUARY 2020-AUGUST 2023
    • 11.8.2 DEALS
    • TABLE 110 DEALS, JANUARY 2020-AUGUST 2023
    • 11.8.3 OTHER DEVELOPMENTS
    • TABLE 111 OTHER DEVELOPMENTS, JANUARY 2020-AUGUST 2023

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 THERMO FISHER SCIENTIFIC INC.
    • TABLE 112 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 MERCK KGAA
    • TABLE 113 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 12.1.3 ABCAM PLC.
    • TABLE 114 ABCAM PLC.: BUSINESS OVERVIEW
    • FIGURE 35 ABCAM PLC.: COMPANY SNAPSHOT (2022)
    • TABLE 115 ABCAM PLC.: DEALS
    • 12.1.4 AGILENT TECHNOLOGIES INC.
    • TABLE 116 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
    • FIGURE 36 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
    • TABLE 117 AGILENT TECHNOLOGIES INC.: PRODUCT LAUNCHES
    • 12.1.5 KANEKA EUROGENTEC S.A.
    • TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW
    • FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022)
    • 12.1.6 SARTORIUS AG
    • TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES
    • 12.1.7 PROMEGA CORPORATION
    • TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW
    • 12.1.8 ELABSCIENCE BIOTECHNOLOGY INC.
    • TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
    • 12.1.9 RAYBIOTECH LIFE, INC.
    • TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW
    • 12.1.10 BMG LABTECH
    • TABLE 124 BMG LABTECH: BUSINESS OVERVIEW
    • TABLE 125 BMG LABTECH: PRODUCT LAUNCHES
    • 12.1.11 BIOTREND CHEMIKALIEN GMBH
    • TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 3H BIOMEDICAL AB
    • 12.2.2 BIOASSAY SYSTEMS
    • 12.2.3 EMELCA BIOSCIENCE
    • 12.2.4 CREATIVE BIOARRAY
    • 12.2.5 TEMPO BIOSCIENCE, INC.
    • 12.2.6 NCARDIA
    • 12.2.7 NOVOCIB
    • 12.2.8 ETON BIOSCIENCE, INC.
    • 12.2.9 CAYMAN CHEMICAL COMPANY
    • 12.2.10 ENZO LIFE SCIENCES, INC.
    • 12.2.11 ABNOVA CORPORATION
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS